16 results
DEFA14A
IMGN
Immunogen, Inc.
24 Jan 24
Additional proxy soliciting materials
4:57pm
or materiality under applicable laws of any of the supplemental disclosures set forth herein. To the contrary, ImmunoGen specifically denies all allegations
8-K
IMGN
Immunogen, Inc.
24 Jan 24
Other Events
4:55pm
be deemed an admission of the legal necessity or materiality under applicable laws of any of the supplemental disclosures set forth herein. To the contrary
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
Intermediate Sub and Purchaser rather than to establish matters as facts and may be subject to standards of materiality applicable to such parties that differ … and correct (without giving effect to any limitation as to “materiality” or “Company Material Adverse Effect”) has not had, individually
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
between the Company, AbbVie Intermediate Sub and Purchaser rather than to establish matters as facts and may be subject to standards of materiality … of such representations and warranties to be true and correct (without giving effect to any limitation as to “materiality” or “Company Material Adverse Effect”) has
DEFA14A
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
, (iv) the accuracy of the representations and warranties contained in the Merger Agreement (subject to specified materiality qualifiers), (v … of materiality different from those generally applicable to the Company’s SEC filings or may have been used for purposes of allocating risk among
DEFA14A
EX-2.1
7xxa4sq
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
EX-2.1
j8x 5zhpk6
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
ebt1bf69z lc9mdotd2
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
46rko30w3vtoud8cr9
11 Jan 21
Results of Operations and Financial Condition
7:01am
8-K
t15i0 yjb2
13 Jan 20
Results of Operations and Financial Condition
6:07am
8-K
EX-1.1
a190i7he26xshl
18 Jun 09
ImmunoGen, Inc. Prices Public Offering of Common Stock
12:00am
8-K
EX-10.1
9gaqpet2bmpd
23 Jun 08
Entry into a Material Definitive Agreement
12:00am
CORRESP
macft0c4y7n4hqr82
30 Jan 07
Correspondence with SEC
12:00am
- Prev
- 1
- Next